BioSpace News Archive

PDS Biotechnology Corporation announced promising interim data from the VERSATILE-002 Phase 2 clinical trial investigating PDS0101 in combination with Merck’s anti-PD-1 therapy, KEYTRUDA®, in patients with unresectable, recurrent or metastatic human papillomavirus 16-positive head and neck cancer.

Relay Therapeutics, Inc. announced complete first-in-human dose escalation data for RLY-4008, an investigational, potent, selective and oral small molecule inhibitor of fibroblast growth factor receptor 2.

Bolt Biotherapeutics, Inc. announced the data from its Phase 1 dose-escalation clinical trial of BDC-1001 that will be presented in a poster session at the American Society of Clinical Oncology 2023 Annual Meeting, being held at McCormick Place in Chicago, Illinois and virtually from June 2-6, 2023.

Xilio Therapeutics, Inc. announced preliminary data from its Phase 1 clinical trial evaluating XTX101, an investigational tumor-activated, Fc-enhanced anti-CTLA-4, in patients with advanced solid tumors.

Aravive, Inc., a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, announced the presentation of updated results from its ongoing Phase 2 trial of batiraxcept in clear cell renal cell carcinoma at the 2023 American Society of Clinical Oncology annual meeting, taking place June 2-6, 2023 in Chicago, IL and virtually.

SpringWorks Therapeutics, Inc. announced that additional data from the Phase 3 DeFi trial assessing the impact of nirogacestat, an investigational gamma secretase inhibitor, on pain, tumor volume and T2 hypersensitivity in adults with desmoid tumors will be presented at the 2023 American Society of Clinical Oncology Annual Meeting, being held June 2-6, 2023.

Vigeo Therapeutics, a clinical-stage immuno-oncology company pioneering novel cancer therapies, announced encouraging new data from its phase I/II expansion study evaluating single-agent activity of VT1021 in patients with recurrent glioblastoma.

Invivoscribe is pleased to announce that their LeukoStrat CDx FLT3 Mutation Assay® has received updated reimbursement by Japan’s Ministry of Health, Labor and Welfare to aid in the selection of patients with newly diagnosed FLT3-ITD positive acute myeloid leukemia who may be eligible to receive treatment with Daiichi Sankyo’s VANFLYTA®.

Theseus Pharmaceuticals, Inc. announced initial dose escalation data from the ongoing phase 1/2 trial of THE-630 in patients with advanced gastrointestinal stromal tumors.

Artiva Biotherapeutics, Inc., a clinical stage company whose mission is to deliver highly effective, off-the-shelf, allogeneic natural killer cell-based therapies, announced the presentation of initial data from the dose-escalation stage of its ongoing Phase 1/2 clinical trial of AB-101.